Zentalis Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Amortized Cost
Zentalis Pharmaceuticals, Inc. (ZNTL) had Debt Securities, Available-for-sale, Amortized Cost of $149.90 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $149.90M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $179.88M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $209.70M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $239.03M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $149.90M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $179.88M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $209.70M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $239.03M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $248.98M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $278.01M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $317.45M 10-K · filed 2026-03-26 |
| 2024-09-30 | $348.34M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $361.46M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $393.87M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $452.69M 10-K · filed 2025-03-26 |
| 2023-09-30 | $406.25M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $286.77M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $356.83M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $395.65M 10-K · filed 2024-02-27 |
| 2022-09-30 | $381.44M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $401.85M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $259.90M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $280.30M 10-Q · filed 2022-11-09 |
| 2021-09-30 | $325.95M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $201.68M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $269.33M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $283.52M 10-Q · filed 2021-11-10 |
| 2020-09-30 | $274.86M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $137.17M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |